P021 SUBCUTANEOUS CERTOLIZUMAB PEGOL IS WELL TOLERATED BY PATIENTS WITH ACTIVE CROHN'S DISEASE: RESULTS FROM TWO PHASE III STUDIES (PRECISE 1 AND 2)